Año 2023 / Volumen 115 / Número 10
Original
Severe and refractory gastrointestinal toxicity due to immune checkpoint inhibitors: clinical experience in a tertiary referral hospital

567-573

DOI: 10.17235/reed.2023.9436/2022

Elena Céspedes Martínez, Virginia Robles Alonso, Claudia Herrera-De Guise, Luis Mayorga, Francesc Casellas, María Roca-Herrera, Natalia Borruel,

Resumen
Introduction: immune checkpoint inhibitors (ICI) are increasingly used to treat several types of cancer. These drugs lead to a wide range of toxicities. Immune-related gastrointestinal adverse events are common and potentially severe. In this manuscript, we recount the real clinical experience in a tertiary center. Methods: a retrospective and observational study was conducted in adult patients under ICI treatment. Included patients had been referred to the Gastrointestinal Service of Hospital Universitario Vall d’Hebron for evaluation of severe toxicities, from January 2017 to January 2020, for whom the clinical, epidemiological and evolutive data were collected. Results: a total of 18 patients were included. Fifty-five percent received anti-programmed cell death protein 1 (PD-1)/anti-programmed death-ligand 1 (anti PD-L1), 11 % received anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) and 33 % received both treatments. The toxicities were manifested as enterocolitis, microscopic colitis and gastritis. Upper gastrointestinal endoscopy was performed in seven patients; all were proved to have histological changes on duodenum biopsies. Treatment was stopped in all patients and steroids were initiated. Sixty-six per cent achieved clinical remission with steroids. Five patients received anti-TNF treatment (infliximab). Only one of the five had responded. Two anti-TNF refractory patients received ustekinumab, with an appropriate clinical response. One patient received apheresis granulocyte as concomitant treatment. A patient with a steroid-dependent course started vedolizumab. Three patients had other immune-related adverse events. Conclusion: gastrointestinal immune-related adverse events are acquiring a higher profile in daily practice and gastroenterologists play an even greater role in the management of these patients.
Resumen coloquial
This text discusses a study conducted on the use of immune checkpoint inhibitors (ICI) and focused on the severe gastrointestinal toxicities that can occur as a result of the treatment. The study included 18 adult patients who were referred to a Gastrointestinal Unit for severe toxicities between January 2017 and January 2020. The toxicities observed were enterocolitis, microscopic colitis, and gastritis. The study found that stopping ICI treatment and initiating steroid treatment led to clinical remission in most patients. However, some patients required additional treatments such as anti-TNF drugs without as good results as reported previously. Authors found Ustekinumab a good option of treatment in refractory to anti-TNF patients. Other treatment options are Granulocyte-apheresis and Vedolizumab. Moreover, clinicians need to start prophylactic antibiotics and antifungal therapies to prevent treatment related complications. It is important to create multidisciplinary committees to aid the clinicians and oncologists should refer patients to an experienced Gastroenterology Unit. IBD patients under ICI treatment should be monitored in their IBD units. Gastrointestinal immune-related adverse events are becoming increasingly common in daily practice, and gastroenterologists play a critical role in managing these patients.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Artículos relacionados

Editorial

Acute pancreatitis: an opportunity for gastroenterology hospitalists?

DOI: 10.17235/reed.2022.8573/2022

Revisión

Practical management of primary biliary cholangitis

DOI: 10.17235/reed.2021.8219/2021

Carta

Neumatosis intestinal en la anorexia nerviosa

DOI: 10.17235/reed.2021.8013/2021

Editorial

Reflex testing. A key tool for the elimination of hepatitis C

DOI: 10.17235/reed.2020.7201/2020

Revisión

Meckel’s diverticulum: clinical features, diagnosis and management

DOI: 10.17235/reed.2018.5628/2018

Carta al Editor

Acute transverse colon volvulus with secondary gastric isquemia. Case report

DOI: 10.17235/reed.2016.4024/2015

Instrucciones para citar
Céspedes Martínez E, Robles Alonso V, Herrera-De Guise C, Mayorga L, Casellas F, Roca-Herrera M, et all. Severe and refractory gastrointestinal toxicity due to immune checkpoint inhibitors: clinical experience in a tertiary referral hospital. 9436/2022


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 1001 veces.
Este artículo ha sido descargado 179 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 18/12/2022

Aceptado: 22/04/2023

Prepublicado: 12/05/2023

Publicado: 09/10/2023

Tiempo de revisión del artículo: 101 días

Tiempo de prepublicación: 145 días

Tiempo de edición del artículo: 295 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas